

8<sup>TH</sup> EDITION

INNOVATIVE THERAPY,  
**MONOCLONAL ANTIBODIES**  
and beyond

**Friday, 26 January 2018**

**Milan**

Fondazione IRCCS Istituto Nazionale dei Tumori  
*Via Giacomo Venezian, 1*



Fondazione IRCCS  
Istituto Nazionale dei Tumori



Regione  
Lombardia

Sistema Socio Sanitario

# Under the patronage of Faculty



**LORENZO CASTAGNOLI** (Milan, Italy)  
**FILIPPO DE BRAUD** (Milan, Italy)  
**MICHELE DEL VECCHIO** (Milan, Italy)  
**SERENA DI COSIMO** (Milan, Italy)  
**MASSIMO DI NICOLA** (Milan, Italy)  
**DAVIDE FRANCESCHINI** (Milan, Italy)  
**JOHN HISCOTT** (Rome, Italy)  
**KARL JOHAN MALMBERG** (Oslo, Norway)  
**NICHOLAS MC GRANAHAN** (London, UK)  
**FRANCESCO SAVERIO MENNINI** (Rome, Italy)  
**FILIPPO PIETRANTONIO** (Milan, Italy)  
**SERENELLA PUPA** (Milan, Italy)  
**LUCIA RIVOLTINI** (Milan, Italy)  
**SABINA SANGALETTI** (Milan, Italy)  
**ELDA TAGLIABUE** (Milan, Italy)  
**CLAUDIO TRIPODO** (Palermo, Italy)  
**CLAUDIO VERNIERI** (Milan, Italy)  
**LAURENCE ZITVOGEL** (Paris, France)

# Presentation

---

*The 8<sup>th</sup> "Innovative therapy, monoclonal antibodies and beyond" Conference will collect leading international experts in the field of immuno-oncology and cancer cell signaling to understand the potential, opportunities and challenges of the immunotherapy and targeted therapies.*

*The key role of the immune system in cancer has been recognized for a long time. Our understanding of the co-evolution of cancer and the immune system has significantly improved, with significant results in clinic. Indeed, the increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumor types. Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care.*

*This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.*

*Finally, several data supporting the combination of immunotherapies and standard treatments open an intriguing challenge, but also a real opportunity for the future therapeutic approaches.*

# Friday, 26 January 2018

---

## WELCOME COFFEE

- 08.30-09.00 Registration  
09.00-09.10 Welcome remarks of Authorities  
09.10-09.20 Introduction • **M. Di Nicola** (Milan, Italy)

## **I SESSION: Preclinical assays and novel biotargets**

Chairmen: **F. de Braud** (Milan, Italy), **M. Del Vecchio** (Milan, Italy)

- 09.20-09.50 Tumor heterogeneity and targeted therapy • **F. de Braud** (Milan, Italy)  
09.50-10.20 Repurposing anti-estrogens to boost drug immune-mediated activity in breast cancer • **E. Tagliabue** (Milan, Italy)  
10.20-10.50 The stromal milieu of cancer-associated immune responses • **C. Tripodo** (Palermo, Italy)  
10.50-11.20 Functional Diversification of Human NK Cells: Implications for Cell-Based Cancer Immunotherapy • **K.J. Malmberg** (Oslo, Norway)  
11.20-11.50 Neoantigen Landscape and its impact on Immune Checkpoint inhibition • **N. Mc Granahan** (London, UK)  
11.50-12.10 General discussion

## **Keynote Lecture**

- 12.10-13.00 Links between the gut microbiome and tumor immuno surveillance • **L. Zitvogel** (Paris, France)  
*Introduced by: M. Di Nicola* (Milan, Italy)  
13.00-14.00 **BUFFET LUNCH**

---

## **II SESSION: Clinical translation**

*Chairmen: M. Di Nicola (Milan, Italy), J. Hiscott (Rome, Italy)*

- 14.00-14.30 Radiotherapy in the era of ICI-based immunotherapy • *D. Franceschini (Milan, Italy)*
- 14.30-15.00 MDSC score • *L. Rivoltini (Milan, Italy)*
- 15.00-15.30 Immune checkpoint inhibitors: new combinations in melanoma • *M. Del Vecchio (Milan, Italy)*
- 15.30-16.00 Economic sustainability of the novel oncologic treatment • *F.S. Mennini (Rome, Italy)*
- 16.00-16.20 General discussion

## **III SESSION: Selected Abstracts**

*Presented by: S. Pupa (Milan, Italy), S. Di Cosimo (Milan, Italy)*

- 16.20-16.40 Improving the selection of HER2-positive gastric cancer patient for Trastuzumab treatment  
*F. Pietrantonio (Milan, Italy)*
- 16.40-17.00 Impact of cyclic fasting mimicking diet (FMD) on cancer patient metabolism • *C. Vernieri (Milan, Italy)*
- 17.00-17.20 Triple-negative breast cancer stem cells up-regulate PD-L1 expression as a potential shield against immune-mediated tumor rejection • *L. Castagnoli (Milan, Italy)*
- 17.20-17.40 Neutrophil extracellular traps and alteration of T cell homeostasis in the bone marrow leukemic niche  
*S. Sangaletti (Milan, Italy)*
- 17.40-18.00 General discussion
  
- 18.00-18.20 Conclusions • *M. Del Vecchio (Milan, Italy)*  
CME Questionnaire compilation

# General Informations

## CONGRESS VENUE

Aula Magna Gianni Bonadonna  
Fondazione IRCCS Istituto Nazionale dei Tumori  
Via G. Venezian, 1 - MILAN

## SCIENTIFIC COMMITTEE

**Filippo de Braud**

**Michele Del Vecchio**

**Massimo Di Nicola**

*Medical Oncology Department*

*Fondazione IRCCS Istituto Nazionale dei Tumori  
Milan*

## ORGANIZING SECRETARIAT



Nadirex International Srl  
Via Riviera 39 · 27100 Pavia  
Tel. +39.0382.525714/35  
Fax +39.0382.525736  
E-mail: [info@nadirex.com](mailto:info@nadirex.com)  
[www.nadirex.com](http://www.nadirex.com)

## OFFICIAL LANGUAGE

English

## CME PROVIDER NR. 265

Nadirex International Srl



## CME

The request for CME credits has been submitted to the Italian Ministry of Health. **ID Nr. 265-211499 - CME credits: Nr. 7,3**

The Congress is intended for the following figures:

- **Physician** (*Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine*)

- **Biologist - Biomedical laboratory technician**

Participants: 100.

*In order to obtain CME credits, participants must:*

*- Attend 90% of the sessions indicated in the programme*

*- Fill in the personal data form, the form evaluating the event, and the learning questionnaire and give them to the Organizational Secretariat at the end of the Congress.*

*The CME certificate will be sent by mail after the Congress to the address given on the personal data form.*

## REGISTRATION

The registration is free and includes:

- Participation in the conference work • Congress Kit
- Certificate of Attendance • CME credits Certificate
- Welcome coffee and lunch as scheduled

## REGISTRATION INSTRUCTIONS

The Congress provides for a maximum of 100 participants.

**Registration online** at [www.nadirex.com](http://www.nadirex.com)

within **January 25th, 2018**.

The Organizing Secretariat will confirm the registration by email.



# Registration Form

Fill in using capital letters and send to:

NADIREX INTERNATIONAL s.r.l.

**Registration online:** [www.nadirex.com](http://www.nadirex.com)

within: **January 25th, 2018**

**CME PROVIDER NR. 265** Nadirex International Srl

ID Nr. 265-211499 - CME credits: Nr. 7,3

Participants: 100.

The Congress is intended for the following figures:

- Physician (Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)

- Biologist

- Biomedical laboratory technician.

**PLEASE COMPLETE THE FOLLOWING DETAILS**

PHISYCIAN       BIOLOGIST       BIOMEDICAL LABORATORY TECHNICIAN

Name ..... Surname .....

Profession ..... Discipline .....

Specialized .....

Clinic/Institute .....

Division/Department .....

Address .....

Postal Code ..... Town/City ..... Province .....

Tel. .... Fax .....

Mobile Tel. ....

E-mail .....

*I authorise the use of my personal data in accordance with Legislative Decree 196/2003*

Date ..... Signature .....



SI RINGRAZIANO LE SEGUENTI AZIENDE  
PER IL CONTRIBUTO NON CONDIZIONANTE:

 **AMGEN**<sup>®</sup>

 Bristol-Myers Squibb

 **MSD**

 **NOVARTIS**

 **TESARO**<sup>®</sup>